#Bioretec #Finland #Tampere #Orthopedic Implants #Sarah van Hellenberg

Sarah van Hellenberg Hubar-Fisher Named Interim CEO of Bioretec

On May 15, 2025, Bioretec Ltd, a pioneering Finnish medical device company, announced the appointment of Sarah van Hellenberg Hubar-Fisher as its new interim CEO. This move is poised to project the company into a new growth phase as it continues to innovate within the medical sector, particularly in the field of absorbable orthopedic implants.

Background of Sarah van Hellenberg Hubar-Fisher

With over 23 years of significant experience in global healthcare leadership and the introduction of new technologies, Sarah van Hellenberg Hubar-Fisher brings invaluable expertise to Bioretec. Her background, which includes a tenure as a member of the Board of Directors and active participation in the Audit Committee, positions her well to take charge immediately.

Kustaa Poutiainen, the Chair of the Board of Directors, expressed enthusiasm regarding Hubar-Fisher's leadership, emphasizing her potential to elevate Bioretec's standing in the competitive landscape of orthopedic devices. He stated, "We are keen to leverage her expertise in bringing Bioretec to the next level with the aim of becoming a leader in absorbable orthopedic implants globally."

Future Endeavors at Bioretec

In her new capacity, Sarah van Hellenberg Hubar-Fisher will also oversee the ongoing recruitment process for a permanent CEO, while continuing to serve on the company's Board. This transition comes at a pivotal moment for Bioretec, as it aims to cement its position within a market worth over USD 9 billion in orthopedic trauma and spine treatment.

Hubar-Fisher expressed her enthusiasm about heading Bioretec through this transformative period. She stated, "I could not be more enthusiastic about the next phases of growth for Bioretec and the opportunity to lead us there. Bioretec is poised to aim for market leadership, and our organization is ready to promote its realization for the patients who deserve and have been waiting for high-quality absorbable implants."

Bioretec’s Innovative Focus

Bioretec is well known for its commitment to developing biodegradable orthopedic implants that enhance bone growth and accelerate healing post-surgery. Their innovative RemeOs™ product line, based on advanced magnesium alloys and hybrid composites, represents a significant advancement in surgical materials—eliminating the need for removal surgery once implanted. This groundbreaking approach could redefine surgical outcomes and promote rehabilitation in patients, focusing on value for both healthcare providers and those they serve.

March 2023 marked the milestone receipt of market authorization in the U.S. for the first RemeOs™ product, followed closely by CE mark approval in January 2025, reinforcing Bioretec's potential for rapid market expansion.

Conclusion

The announcement of Sarah van Hellenberg Hubar-Fisher as interim CEO marks a critical juncture for Bioretec as the company aims to navigate its next steps in the medical device landscape. With a strong background and visionary leadership, Hubar-Fisher's tenure is set to propel Bioretec forward in its mission to transform orthopedic treatment through innovative solutions. The coming months will be pivotal as both the leadership team and the Board strive to fulfill the company's ambitious goals to enhance patient outcomes worldwide.

For more information on Bioretec and its products, visit bioretec.com.